<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853407</url>
  </required_header>
  <id_info>
    <org_study_id>LY03005/CT-CHN-305</org_study_id>
    <nct_id>NCT04853407</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)</brief_title>
  <official_title>A Phase III, A Multicenter, Double-blind, Randomized, Placebo-controlled Study Verify the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets for Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if LY03005 is effective and safe in improve MADRS&#xD;
      score, as compared to placebo (no medicine) in participants with Major Depressive Disorder&#xD;
      (MDD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of two periods: a screening period of 1 week and a double-blind treatment&#xD;
      period (8 weeks). After the screening period, 588 enrolled subjects were randomized into one&#xD;
      of 3 study groups in the 1:1:1 ratio, 2 LY03005 treatment groups with different dose or 1&#xD;
      placebo group. Subjects were given investigatory drug or placebo according to the protocol,&#xD;
      followed up at the end of 1, 2, 4 6, and 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2018</start_date>
  <completion_date type="Actual">December 24, 2020</completion_date>
  <primary_completion_date type="Actual">December 24, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery- Åsberg Depression Rating Scale(MADRS)</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Changes from baseline in the 10-items Montgomery- Åsberg Depression Scales (MADRS) total scores at the end of treatment.&#xD;
The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>17 items Hamilton Depression Scales (HAM-D17)</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total scores at the end of treatment.&#xD;
HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50; higher score indicates more depression.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">558</enrollment>
  <condition>Major Depressive Disorder (MDD)</condition>
  <arm_group>
    <arm_group_label>LY03005 extended-release tablets 80 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY03005 extended-release tablets 160 mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>orally once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY03005 extended-release tablet</intervention_name>
    <description>orally once a day</description>
    <arm_group_label>LY03005 extended-release tablets 160 mg group</arm_group_label>
    <arm_group_label>LY03005 extended-release tablets 80 mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally once a day</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18 to 65 years subjects from outpatients;&#xD;
&#xD;
          2. Subjects currently meet the Diagnostic and Statistical Manual of Manual Disorders,&#xD;
             fifth Edition(DSM-5) criteria for MDD with either single or recurrent episodes&#xD;
             (296.2/296.3) without psychotic characteristics;&#xD;
&#xD;
          3. Subjects has a total score of the Montgomery- Åsberg Depression Scale (MADRS) ≥26&#xD;
             points at screening;&#xD;
&#xD;
          4. Subjects has a clinical Global Impression -severity illness (CGI-S) score≥4 points at&#xD;
             screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic or known to be allergic to venlafaxine and desvenlafaxine;&#xD;
&#xD;
          2. Subjects with MDD who were not responsive to the previous venlafaxine treatment with&#xD;
             sufficient amount and duration and to at least two different mechanisms of action&#xD;
             antidepressants with adequate amount and duration in the past;&#xD;
&#xD;
          3. There is a clear suicide attempt or behavior and score of the 10th item (suicidal&#xD;
             ideation) in MADRS scale is 4 points or greater;&#xD;
&#xD;
          4. Pregnant or lactating women,women who have a planned pregnancy in the near future;&#xD;
&#xD;
          5. Subjects meet the diagnostic criteria for other psychotic disorders(except for MDD) in&#xD;
             DSM-5, such as Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and&#xD;
             Related Disorders, Obsessive-Compulsive and related Disorders, post-traumatic stress&#xD;
             disorder, separation disorders, anorexia nervosa or bulimia and personality disorder;&#xD;
&#xD;
          6. Subjects who meet the diagnostic criteria for substance or alcohol abuse (excluding&#xD;
             nicotine or caffeine) 6 months prior to the screening;&#xD;
&#xD;
          7. MDD secondary to other mental illnesses or physical illnesses;&#xD;
&#xD;
          8. Those with a history of seizures (except for convulsions caused by febrile seizures in&#xD;
             children).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyan Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Sixth Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sixth Hospital of Peking University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

